Q32 Income Tax Expense vs Research Development Analysis

QTTB Stock

24.55 2.49 9.21%

Q32 Bio financial indicator trend analysis is much more than just breaking down Q32 Bio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Q32 Bio is a good investment. Please check the relationship between Q32 Bio Income Tax Expense and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.

Income Tax Expense vs Research Development

Income Tax Expense vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Q32 Bio Income Tax Expense account and Research Development. At this time, the significance of the direction appears to have weak relationship.

The correlation between Q32 Bio's Income Tax Expense and Research Development is 0.33. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Research Development in the same time period over historical financial statements of Q32 Bio, assuming nothing else is changed. The correlation between historical values of Q32 Bio's Income Tax Expense and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Q32 Bio are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Income Tax Expense i.e., Q32 Bio's Income Tax Expense and Research Development go up and down completely randomly.

Correlation Coefficient

0.33

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Income Tax Expense

Research Development

Most indicators from Q32 Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Q32 Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.At present, Q32 Bio's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.03, whereas Tax Provision is forecasted to decline to about 53 K.

	2022	2023	2024 (projected)
Total Operating Expenses	45.9M	92.7M	69.8M
Cost Of Revenue	2.6M	578K	549.1K

Total Operating Expenses Cost Of Revenue

Q32 Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Investments	Inventory	Short Long Term Debt Total	Short Term Debt
Total Assets		0.58	0.25	0.79	0.7	-0.6	-0.75	0.58	0.58	0.62	-0.32	-0.37	0.89	0.55	0.24	0.5	0.71	0.28	0.5	0.89	0.92	0.28	0.31	0.39	-0.27	-0.12
Other Current Liab	0.58		0.58	0.38	0.66	-0.54	-0.58	0.13	0.64	0.36	-0.45	-0.21	0.54	0.17	0.4	0.34	0.31	0.43	0.41	0.53	0.64	0.38	0.29	0.46	0.23	0.35
Total Current Liabilities	0.25	0.58		-0.14	0.3	-0.12	-0.29	0.24	0.34	0.15	-0.66	-0.1	0.25	0.55	0.47	0.43	0.38	0.66	0.56	0.26	0.13	0.52	0.34	0.57	0.69	0.89
Total Stockholder Equity	0.79	0.38	-0.14		0.79	-0.61	-0.33	0.54	0.5	0.24	0.24	-0.06	0.88	-0.01	-0.34	-0.08	0.66	-0.25	-0.09	0.88	0.68	-0.25	0.41	-0.19	-0.3	-0.44
Property Plant And Equipment Net	0.7	0.66	0.3	0.79		-0.68	-0.2	0.58	0.65	-0.03	0.16	0.22	0.9	0.09	-0.15	-0.1	0.74	0.14	-0.05	0.9	0.56	-0.27	0.61	-0.12	0.16	0.01
Net Debt	-0.6	-0.54	-0.12	-0.61	-0.68		0.44	-0.28	-0.97	-0.17	-0.08	0.03	-0.67	-0.11	-0.12	-0.08	-0.24	-0.13	-0.1	-0.66	-0.65	-0.01	0.14	-0.13	0.16	0.2
Retained Earnings	-0.75	-0.58	-0.29	-0.33	-0.2	0.44		-0.2	-0.52	-0.94	0.73	0.81	-0.43	-0.59	-0.64	-0.87	-0.22	-0.46	-0.84	-0.43	-0.84	-0.78	0.22	-0.84	0.42	0.04
Accounts Payable	0.58	0.13	0.24	0.54	0.58	-0.28	-0.2		0.26	0.18	0.02	-0.05	0.63	0.4	-0.25	0.14	0.88	0.13	0.17	0.64	0.39	-0.1	0.41	0.02	-0.1	-0.1
Cash	0.58	0.64	0.34	0.5	0.65	-0.97	-0.52	0.26		0.23	-0.11	-0.12	0.64	0.22	0.27	0.22	0.25	0.3	0.26	0.64	0.62	0.18	-0.13	0.31	-0.02	0.01
Non Current Assets Total	0.62	0.36	0.15	0.24	-0.03	-0.17	-0.94	0.18	0.23		-0.73	-0.93	0.25	0.52	0.51	0.86	0.17	0.29	0.81	0.25	0.71	0.8	-0.26	0.8	-0.53	-0.13
Non Currrent Assets Other	-0.32	-0.45	-0.66	0.24	0.16	-0.08	0.73	0.02	-0.11	-0.73		0.69	0.0	-0.68	-0.78	-0.88	-0.05	-0.63	-0.92	0.0	-0.38	-0.96	0.1	-0.94	-0.11	-0.55
Other Assets	-0.37	-0.21	-0.1	-0.06	0.22	0.03	0.81	-0.05	-0.12	-0.93	0.69		-0.07	-0.37	-0.44	-0.81	-0.03	-0.23	-0.75	-0.07	-0.44	-0.79	0.37	-0.75	0.52	0.14
Cash And Short Term Investments	0.89	0.54	0.25	0.88	0.9	-0.67	-0.43	0.63	0.64	0.25	0.0	-0.07		0.35	-0.02	0.17	0.82	0.19	0.2	1.0	0.69	-0.07	0.52	0.07	-0.07	-0.1
Net Receivables	0.55	0.17	0.55	-0.01	0.09	-0.11	-0.59	0.4	0.22	0.52	-0.68	-0.37	0.35		0.68	0.79	0.43	0.75	0.83	0.35	0.45	0.59	0.06	0.72	-0.01	0.35
Common Stock Shares Outstanding	0.24	0.4	0.47	-0.34	-0.15	-0.12	-0.64	-0.25	0.27	0.51	-0.78	-0.44	-0.02	0.68		0.81	-0.18	0.84	0.83	-0.03	0.35	0.75	-0.29	0.86	-0.01	0.41
Non Current Liabilities Total	0.5	0.34	0.43	-0.08	-0.1	-0.08	-0.87	0.14	0.22	0.86	-0.88	-0.81	0.17	0.79	0.81		0.15	0.7	0.99	0.17	0.53	0.88	-0.23	0.95	-0.28	0.2
Other Current Assets	0.71	0.31	0.38	0.66	0.74	-0.24	-0.22	0.88	0.25	0.17	-0.05	-0.03	0.82	0.43	-0.18	0.15		0.21	0.2	0.83	0.42	-0.1	0.73	0.02	0.08	0.07
Other Stockholder Equity	0.28	0.43	0.66	-0.25	0.14	-0.13	-0.46	0.13	0.3	0.29	-0.63	-0.23	0.19	0.75	0.84	0.7	0.21		0.76	0.2	0.23	0.51	0.05	0.71	0.17	0.52
Total Liab	0.5	0.41	0.56	-0.09	-0.05	-0.1	-0.84	0.17	0.26	0.81	-0.92	-0.75	0.2	0.83	0.83	0.99	0.2	0.76		0.2	0.51	0.89	-0.16	0.97	-0.15	0.33
Total Current Assets	0.89	0.53	0.26	0.88	0.9	-0.66	-0.43	0.64	0.64	0.25	0.0	-0.07	1.0	0.35	-0.03	0.17	0.83	0.2	0.2		0.69	-0.07	0.53	0.07	-0.07	-0.09
Common Stock	0.92	0.64	0.13	0.68	0.56	-0.65	-0.84	0.39	0.62	0.71	-0.38	-0.44	0.69	0.45	0.35	0.53	0.42	0.23	0.51	0.69		0.4	0.03	0.48	-0.39	-0.21
Current Deferred Revenue	0.28	0.38	0.52	-0.25	-0.27	-0.01	-0.78	-0.1	0.18	0.8	-0.96	-0.79	-0.07	0.59	0.75	0.88	-0.1	0.51	0.89	-0.07	0.4		-0.34	0.96	-0.05	0.39
Short Term Investments	0.31	0.29	0.34	0.41	0.61	0.14	0.22	0.41	-0.13	-0.26	0.1	0.37	0.52	0.06	-0.29	-0.23	0.73	0.05	-0.16	0.53	0.03	-0.34		-0.3	0.49	0.33
Inventory	0.39	0.46	0.57	-0.19	-0.12	-0.13	-0.84	0.02	0.31	0.8	-0.94	-0.75	0.07	0.72	0.86	0.95	0.02	0.71	0.97	0.07	0.48	0.96	-0.3		-0.09	0.38
Short Long Term Debt Total	-0.27	0.23	0.69	-0.3	0.16	0.16	0.42	-0.1	-0.02	-0.53	-0.11	0.52	-0.07	-0.01	-0.01	-0.28	0.08	0.17	-0.15	-0.07	-0.39	-0.05	0.49	-0.09		0.88
Short Term Debt	-0.12	0.35	0.89	-0.44	0.01	0.2	0.04	-0.1	0.01	-0.13	-0.55	0.14	-0.1	0.35	0.41	0.2	0.07	0.52	0.33	-0.09	-0.21	0.39	0.33	0.38	0.88

Click cells to compare fundamentals

Q32 Bio Account Relationship Matchups

Q32 Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	310.6M	263.7M	35.2M	61.8M	306.1M	190.9M
Other Current Liab	9.0M	9.8M	4.5M	8.5M	7.0M	7.3M
Total Current Liabilities	12.4M	22.7M	7.2M	57.9M	11.6M	20.5M
Total Stockholder Equity	258.5M	196.0M	(89.2M)	(130.7M)	73.0M	61.0M
Property Plant And Equipment Net	42.7M	42.9M	203K	9.2M	650K	617.5K
Net Debt	(53.8M)	(202.0M)	(27.3M)	838K	(37.9M)	(39.8M)
Retained Earnings	(199.7M)	(328.4M)	(90.5M)	(133.3M)	(542.1M)	(515.0M)
Accounts Payable	2.6M	4.7M	2.7M	1.4M	3.2M	3.4M
Cash	53.8M	217.4M	32.2M	43.9M	39.3M	67.1M
Non Current Assets Total	44.0M	44.2M	1.2M	14.9M	222.2M	233.3M
Cash And Short Term Investments	262.4M	217.4M	32.2M	43.9M	82.7M	99.4M
Common Stock Shares Outstanding	2.3M	2.6M	3.1M	3.2M	3.2M	2.8M
Liabilities And Stockholders Equity	310.6M	263.7M	35.2M	61.8M	306.1M	190.9M
Non Current Liabilities Total	39.7M	45.1M	117.1M	134.6M	221.6M	232.6M
Other Current Assets	3.8M	1.7M	842K	1.9M	1.3M	1.8M
Other Stockholder Equity	458.0M	524.4M	1.3B	1.3B	615.1M	620.3M
Total Liab	52.1M	67.7M	124.4M	192.5M	233.1M	244.8M
Total Current Assets	266.6M	219.6M	34.0M	46.9M	83.9M	101.6M
Accumulated Other Comprehensive Income	(77K)	183K	(7K)	(404K)	(5K)	(5.3K)
Common Stock	3K	4K	5K	1K	6K	3.1K
Current Deferred Revenue	809K	5.6M	3.2M	14.5M	16.7M	17.5M
Short Term Investments	176.5M	208.6M	47.5M	141.0M	43.4M	41.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:

How To Invest In Q32

Details

Is Q32 Stock a good investment?

Details

What is Q32 Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.50)

Revenue Per Share

(1.24)

The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Q32 Income Tax Expense vs Research Development Analysis

Income Tax Expense vs Research Development

Income Tax Expense vs Research Development Correlation Analysis

Correlation Coefficient

Income Tax Expense

Research Development

Q32 Bio fundamental ratios Correlations

Q32 Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Q32 Bio fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Inventory	+ 0.97	Total Liab
Inventory	+ 0.96	Current Deferred Revenue
Inventory	+ 0.95	Non Current Liabilities Total
Common Stock	+ 0.92	Total Assets

Cash	- 0.97	Net Debt
Current Deferred Revenue	- 0.96	Non Currrent Assets Other
Inventory	- 0.94	Non Currrent Assets Other
Non Current Assets Total	- 0.94	Retained Earnings
Other Assets	- 0.93	Non Current Assets Total
Total Liab	- 0.92	Non Currrent Assets Other